Premium
Psoriasiform exfoliative erythroderma induced by golimumab
Author(s) -
Mateo S.,
GarcíaMartínez F. J.,
SánchezAguilar D.,
Amarelo J.,
Toribio J.
Publication year - 2014
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/ced.12402
Subject(s) - golimumab , medicine , exfoliative dermatitis , erythroderma , dermatology , psoriasis , psoriatic arthritis , ankylosing spondylitis , rheumatoid arthritis , spondylitis , tumor necrosis factor alpha , infliximab , secukinumab , arthritis , immunology
Summary Golimumab is a fully human anti‐tumour necrosis factor ( TNF )‐α monoclonal antibody approved for use in the treatment of active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Psoriasis induced by treatment with anti‐ TNF drugs is well documented, but to our knowledge, the development of clinical features of psoriasiform exfoliative erythroderma during treatment with golimumab has not been previously described.